11 February 2013 | News | By BioSpectrum Bureau
The divestment is part of Eisai's new strategy to bring in efficiency in the system
Singapore: Eisai's Taiwan subsidiary Eisai Taiwan has entered into an agreement to divest its Tainan plant to Taiwanese pharmaceutical company Bora.
Since commencing operations in 1974, the Tainan plant has performed its role as a production base that serves emerging countries, particularly in Asia. In recent years, however, the environment surrounding the pharmaceutical industry has been undergoing rapid changes. In order to better and more accurately identify and respond to diversifying customer needs in the pharmaceutical industry, Eisai underwent a transformation in October 2012 that saw its existing production structure, which was based on manufacturing sites managed by region, shift to a globally integrated, unit-based structure organized by product family.
Based on a review conducted under the new production structure, which evaluated Eisai's global supply chain strategy in terms of efficiency and productivity, Eisai and Eisai Taiwan decided to divest the Tainan plant to Bora. Eisai Taiwan will now move ahead with the procedures necessary to complete the divestment based on local laws and regulations, with the divestment expected to be completed by September 2013.